Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:16 PM
Ignite Modification Date:
2025-12-24 @ 9:16 PM
NCT ID:
NCT00329004
Eligibility Criteria:
Inclusion Criteria:
* Men and women 18 and older
* Diagnosis of any solid tumor
* ECOG performance status score 0-1
* Prior chemo-therapy, immunotherapy or radiotherapy with at least 4 weeks since the last treatment
* Treatment with VEGFR2 or HER1 TKI allowed but not both (for instance Avastin or Tarceva, but not both)
Exclusion Criteria:
* Treatment with other TKIs within the past 4 weeks
* Patients with brain metastasis
* Patients with centrally located squamous cell carcinoma of the lung
* Major gastrointestinal surgery which may affect absorption of the drug
* Any surgery within last 4 weeks
* History of thromboembolism
* Severe unmanageable diarrhea
* Subjects in Part B will have Non-Small Cell Lung Cancer (NSCLC)
* Part B/Cohort I erlotinib-naive subjects
* Part B/Cohort II subjects who have experienced disease progression while receiving erlotinib (erlotinib-resistant subjects)
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT00329004
Study Brief:
Protocol Section:
NCT00329004